

## Saskatchewan Immunization Manual Amendments **October 2018**

**Instructions:** Please remove and discard the corresponding pages in each chapter section and insert the amended pages as noted below in each corresponding chapter section dated **October 2018**.

### Chapter 5 – Immunization Schedules

- TOC page 2
  - Appendix 5.2 renamed as Publicly Funded MMR Vaccine Eligibility
- P. 5 Section 1.4 Children 1 Year and Older but less than 7 Years Who Present for Immunizations
  - **New** footnote #11 for MMRV and MMR - Refer to [Appendix 5.2: Publicly Funded MMR Vaccine Eligibility](#).
- P. 6 Section 1.5 Children 7 to 17 Years Who Present for Immunizations
  - **New** footnote #14 for MMRV and MMR - Refer to [Appendix 5.2: Publicly Funded MMR Vaccine Eligibility](#).
- P. 7 Section 1.6 Adults 18 Years and Older Who Present for Immunizations
  - **Revised** footnote #2 for MMR last sentence - Refer to [Appendix 5.2: Publicly Funded MMR Vaccine Eligibility](#).
- P. 8 Section 1.7 Recommended Publicly Funded Immunizations for Adults Who Completed a Primary Childhood Vaccine Series
  - **Revised** MMR sentence - Refer to [Appendix 5.2: Publicly Funded MMR Vaccine Eligibility](#) to assess eligibility.
- P. 9 Section 1.8 Publicly Funded Vaccine Eligibility Criteria
  - Appendix name change for measles and mumps - Refer to [Appendix 5.2: Publicly Funded MMR Vaccine Eligibility](#).
  - New statements for Rubella:
    - According to CIG, 1 dose of rubella is considered sufficient for immunity in all ages. Refer to [Appendix 5.2: Publicly Funded MMR Vaccine Eligibility](#).
    - Documented serological non-immune individuals who have documentation of receiving two previous doses of rubella-containing vaccines are ineligible to receive further doses of rubella-containing vaccine; document as a non-responder.
- P. 11 Section 2.1 Minimum Intervals for Specific Vaccine Series
  - Previous #12 footnote pertaining to varicella deleted. Former #13 is now #12.
- P. 21 Section 4.1 Unknown or Uncertain Immunization Status
  - Content update second paragraph - Measles, Mumps, Rubella – see [Appendix 5.2: Publicly Funded MMR Vaccine Eligibility](#).
- P. 27 Appendix 5.2: Publicly Funded MMR Vaccine Eligibility (applies to everyone ≥ 1 year old)
  - **Please review this revised algorithm carefully.** As 1 dose of rubella is accepted as immunity by CIG, the content in the #1 and the 3<sup>rd</sup>, 4<sup>th</sup> and 5<sup>th</sup> boxes have been revised.

### Chapter 7 Special Populations

- P. 10 Section 2.10A: Recommended Vaccines – Malignancies / Cancer
  - Appendix name for MMR corrected.
- P. 23 Section 5.2.A Publicly Funded Vaccines – Pregnancy
  - Footnote #2 has been revised with reference to [Appendix 5.2: Publicly Funded MMR Vaccine Eligibility](#).
- P. 27 Section 6.3 Publicly Funded Vaccines Health Care Worker – Eligible for Publicly Funded Vaccines
  - For varicella, measles, mumps and rubella, documentation of immunization is now listed as the first criterion for immunity.
  - Refer to Chapter 5, Appendix 5.2: Publicly Funded MMR Vaccine Eligibility to assess MMR dose eligibility is **now** stated in the Recommendations column for measles, mumps and rubella.
- P. 41 Appendix 7.8: Publicly Funded Immigrant and Refugee Immunization and Serology Recommendations
  - New title of Appendix 5.2: [Publicly Funded MMR Vaccine Eligibility](#) noted in table.

## Saskatchewan Immunization Manual Amendments **October 2018**

### Chapter 8 Administration of Biological Products

- P. 4 Section 1.3.3 Vials
  - #8 now reads: Hold the vial upside down and withdraw all contents to ensure client receives full concentration of antigens.
    - Single dose vial - withdraw all contents to ensure client receives full concentration of antigens.
    - Multidose vial - withdraw the required quantity of biological product into the syringe.
- P. 4 Section 1.3.4 Vaccines with Diluents
  - #2-third bullet now reads: Inject diluent into vaccine vial and gently agitating to thoroughly dissolve the lyophilized powder. Draw up all contents to ensure client receives full concentration of antigens.
- P. 5 Section 1.3.5 Ampoules
  - #5 now reads: Draw up all contents to ensure client receives full concentration of antigens using a sterile syringe and needle. It is not necessary to change needles between drawing up the biological product into the syringe and administering it to the client.

### Chapter 10 Biological Products

- Boostrix – ingredients updated.
- MMR vaccines –footnote #1
  - Revised to reflect Ministry letter regarding MMR eligibility for children 6-11 months of age.
- The following sentence has been added to MMR and MMRV vaccines in either the indication section or as a footnote: According to CIG, 1 dose of rubella is considered sufficient for immunity in all ages. Refer to Appendix 5.2: *Publicly Funded MMR Vaccine Eligibility*.
- Prevnar 13 – Page 2 of 2 and Pneumovax 23 page 2 of 2 footnote #3
  - **New** noted added: NOTE: 1-year minimum interval is required if Pneu-P-23 is given before Pneu-C-13(all ages), and an 8 week interval is required if Pneu-C-13 is given before Pneu-P-23 for all ages. HSCT recipients may be an exception to this recommendation.
- Pneumovax 23
  - Previous footnote #5 is now Footnot#4.

### Chapter 14 Appendices

- P. 27 Select Immunization-Related Letters from the Ministry of Health
  - MMR Immunization Questions and Answers Regarding Travelling Infants added.